TriangleDISEASE & TREATMENT SETTING
Squamous Cell Carcinoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Squamous Cell Carcinoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 4 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
24 more-specific settings
Keytruda: metastatic Squamous Cell Carcinoma after prior therapy →KEYTRUDA QLEX: unresectable metastatic Squamous Cell Carcinoma (first-line) →KEYTRUDA: resectable locally advanced Squamous Cell Cancer with PD-L1 stated without a specific alteration (neoadjuvant) →Docetaxel: locally advanced Squamous Cell Carcinoma →TEVIMBRA: unresectable metastatic Squamous Cell Carcinoma with PD-L1 stated without a specific alteration (first-line) →OPDIVO QVANTIG: metastatic Squamous Cell Carcinoma after prior therapy →ERBITUX: advanced Squamous Cell Carcinoma with EGFR stated without a specific alteration →KEYTRUDA QLEX: resectable locally advanced Squamous Cell Cancer with PD-L1 stated without a specific alteration (neoadjuvant) →TEVIMBRA: unresectable metastatic Squamous Cell Carcinoma after prior therapy →KEYTRUDA: metastatic Squamous Cell Carcinoma →UNLOXCYT: metastatic Squamous Cell Carcinoma →ERBITUX: metastatic Squamous Cell Carcinoma →OPDIVO: unresectable metastatic Squamous Cell Carcinoma with PD-L1 stated without a specific alteration (first-line) →KEYTRUDA QLEX: metastatic Squamous Cell Carcinoma →KEYTRUDA: unresectable metastatic Squamous Cell Carcinoma (first-line) →OPDIVO: metastatic Squamous Cell Carcinoma after prior therapy →BEIZRAY: locally advanced Squamous Cell Carcinoma →ZYNYZ: metastatic Squamous Cell Carcinoma (first-line) →OPDIVO: unresectable metastatic Squamous Cell Carcinoma after prior therapy →ERBITUX: metastatic Squamous Cell Carcinoma (first-line) →UNLOXCYT: metastatic Squamous Cell Carcinoma with PD-L1 stated without a specific alteration →YERVOY: unresectable metastatic Squamous Cell Carcinoma with PD-L1 stated without a specific alteration (first-line) →OPDIVO QVANTIG: unresectable metastatic Squamous Cell Carcinoma with PD-L1 stated without a specific alteration (first-line) →DOCIVYX: locally advanced Squamous Cell Carcinoma →
Study evidence for this setting
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Pilot Study of Acupuncture Treatment for Dysphagia
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Indication-specific source history
2016-08-05 · Keytruda (pembrolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-squamous-cell-carcinoma
- event id
- fda-15126d920234e7d0
- event date
- 2016-08-05
- event kind
- accelerated-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy
- match phrase
- squamous cell carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-40c73f0c8bcae446ccf1
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-06-10 · Keytruda (pembrolizumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-squamous-cell-carcinoma
- event id
- fda-83efaafcd2b18531
- event date
- 2019-06-10
- event kind
- traditional-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy
- match phrase
- squamous cell carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-40c73f0c8bcae446ccf1
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-05-15 · retifanlimab-dlwr with carboplatin/paclitaxel and as monotherapy · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-squamous-cell-carcinoma
- event id
- notice-486887f9ffe5cde3
- event date
- 2025-05-15
- event kind
- approval-notification
- drug or regimen
- retifanlimab-dlwr with carboplatin/paclitaxel and as monotherapy
- source indication text
- FDA approved retifanlimab-dlwr with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal . The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
- match phrase
- squamous cell carcinoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-8dc0436208642c00
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-06-12 · neoadjuvant and adjuvant pembrolizumab · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-squamous-cell-carcinoma
- event id
- notice-5a8a2499aaa62c3e
- event date
- 2025-06-12
- event kind
- approval-notification
- drug or regimen
- neoadjuvant and adjuvant pembrolizumab
- source indication text
- FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent.
- match phrase
- squamous cell carcinoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-9dafa5ab92723dbc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-10-08 · cemiplimab-rwlc · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-squamous-cell-carcinoma
- event id
- notice-a2b21cb9c1827114
- event date
- 2025-10-08
- event kind
- approval-notification
- drug or regimen
- cemiplimab-rwlc
- source indication text
- FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
- match phrase
- squamous cell carcinoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-b93fc8a06f72822f
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-squamous-cell-carcinoma
- binding id
- ncit-C2929
- source collection
- ncit-concept
- source key
- C2929
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice